Targeting PD-1 and PD-L1 for lung cancer therapy
Joseph Paul Eder
CheckMate 153 trial: how long should nivolumab be taken for?
NSCLC: the increasing need for PD-L1 testing
Overview of the world of EGFR mutant lung cancers
Immune adverse events of checkpoint inhibitors